| Bioactivity | iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. | ||||||
| Invitro | iRGD peptide-mediated tumor penetration occurs in three steps: binding to αv-integrins on tumor vasculature or tumor cells, exposure by proteolysis of a C-terminal motif that binds to neuropilin-1 (NRP-1) and cell internalization. iRGD peptide inserted in the ICOVIR15K fiber C terminus enhances binding and internalization only in MCF7 cells, which express NRP-1 and integrins. iRGD insertion does not impair virus infection and replication[1]. iRGD peptide alone has no obvious effect on gastric cancer cells, and when combined with 5-FU, iRGD peptide (0.3 μmol/mL) enhances the chemotherapy efficacy of 5-FU on gastric cancer cells through NRP1[2]. | ||||||
| Name | iRGD peptide | ||||||
| CAS | 1392278-76-0 | ||||||
| Shortening | CRGDKGPDC (Disulfide bridge:Cys1-Cys9) | ||||||
| Formula | C35H57N13O14S2 | ||||||
| Molar Mass | 948.04 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
iRGD peptide
CAS: 1392278-76-0 F: C35H57N13O14S2 W: 948.04
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.